Despite these studies, the specific mechanisms by which RIG-I activity influence CD8+ T cell differentiation and cytotoxicity remain poorly understood, with most research focusing on the intrinsic role of RIG-I in cancer cells or APCs, and indirect roles in bolstering CD8+ T cell responses. The gene discussed is RIGI; the disease is cancer.